Managing functional bowel disorders from the top down: Lessons from a well-designed treatment trial

Gastroenterology

Volumn 125, Issue 1, 2003, Pages 249-253

  Clouse, Ray E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COLON DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; EDITORIAL; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; IRRITABLE COLON; PAIN; PRIORITY JOURNAL; PSYCHOTHERAPY; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0037716343     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00808-4     Document Type: Editorial

References (24)

1. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998;115:1263-1271.
2. Hollerbach S, Bulat R, May A, Kamath MV, Upton AR, Fallen EL, Tougas G. Abnormal cerebral processing of oesophageal stimuli in patients with noncardiac chest pain (NCCP). Neurogastroenterol Motil 2000;12:555-565.
3. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122:1140-1156.
4. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44:400-406.
5. Riley JL III, Robinson ME, Kvaal SA, Gremillion HA. Effects of physical and sexual abuse in facial pain: direct or mediated? Cranio 1998;16:259-266.
6. Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH. The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25-30.
7. Drossman DA, Whitehead WE, Toner BB, Diamant NE, Hu YJB, Bangdiwala SI, Jia H. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000;95:974-980.
8. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and syndromes. J Fam Pract 1999;48:980-990.
9. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI. Cognitive-behavioral therapy vs. education and desipramine vs. placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125: 19-31.
10. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-416.
11. Prakash C, Lustman PJ, Freedland KE, Clouse RE. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci 1998;43:1951-1956.
12. Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, Matson RW, Stein GE, Dean GE, Halvorsen NA, Rosen LW. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987;32:257-266.
13. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
14. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996;31:318-325.
15. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-227.
16. Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC, Whooley MA. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003;163:949-957.
17. Clouse RE, Lustman PJ. Antidepressants for irritable bowel syndrome. In: Camilleri M, Spiller RC, eds. Irritable bowel syndrome: diagnosis and treatment. Philadelphia: Saunders, 2002:161-171.
18. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-317.
19. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108-2131.
20. Toner BB, Segal ZV, Emmott SD, Myran D. Cognitive-behavioral treatment of irritable bowel syndrome: the brain-gut connection. New York: Guilford, 2000.
21. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 129:613-621.
22. Inouye SK, Bogardus ST Jr, Williams CS, Leo-Summers L, Agostini JV. The role of adherence on the effectiveness of nonpharmacologic interventions. Arch Intern Med 2003;163:958-964.
23. Prakash C, Owens MM, Freedland KE, Lustman PJ, Clouse RE. Contributors to global symptom status in patients with functional GI disorders and the impact of tricyclic antidepressants (abstr). Gastroenterology 2000;118:2069.
24. Mertz H, Pickens D, Morgan V. Amitriptyline reduces activation of the anterior cingulated cortex in irritable bowel syndrome patients during rectal pain (abstr). Gastroenterology 2003 124(suppl 1):A47.